ReShape Lifesciences Inc. (RSLS)

0.1622 -0.0088 (-5.15%) At close: 04:00PM EDT

ReShape Lifesciences Inc.

18 Technology Drive
Suite 110
Irvine, CA 92618
United States
949-429-6680
https://www.reshapelifesciences.com

Sector(s): Healthcare
Industry: Medical Devices
Full Time Employees: 29

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Dan W. Gladney	Executive Chair	129.5k	N/A	1953
Mr. Paul F. Hickey	CEO, President & Director	506.42k	N/A	1965
Mr. Thomas Stankovich	Senior VP & CFO	307.12k	N/A	1961
Dr. Mark B. Knudson Ph.D.	Co-Founder and Special Advisor to the CEO	33k	N/A	1949
Dr. Katherine S. Tweden Ph.D.	Co-Founder	338.41k	N/A	1961
Mr. Al Diaz	Vice President of Operations and R&D	N/A	N/A	N/A
Dr. Dov Gal D.V.M., M.B.A.	VP of Regulatory Clinical Quality & Compliance Officer	N/A	N/A	N/A
Jody B. Dahlman	Director of Communications	N/A	N/A	N/A
Mr. Naqeeb A. Ansari	Senior Vice President of Global Commercial Operations	327.46k	N/A	1961

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.

Corporate Governance

ReShape Lifesciences Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.